These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25339989)

  • 21. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth of ligand-target interaction data in ChEMBL is associated with increasing and activity measurement-dependent compound promiscuity.
    Hu Y; Bajorath J
    J Chem Inf Model; 2012 Oct; 52(10):2550-8. PubMed ID: 22978710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analyzing Promiscuity at the Level of Active Compounds and Targets.
    Bajorath J
    Mol Inform; 2016 Dec; 35(11-12):583-587. PubMed ID: 27870240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of search parameters and criteria on compound selection, promiscuity, and pan assay interference characteristics.
    Hu Y; Bajorath J
    J Chem Inf Model; 2014 Nov; 54(11):3056-66. PubMed ID: 25329977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds.
    Jasial S; Hu Y; Bajorath J
    J Med Chem; 2017 May; 60(9):3879-3886. PubMed ID: 28421750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs as habitable planets in the space of dark chemical matter.
    Siramshetty VB; Preissner R
    Drug Discov Today; 2018 Mar; 23(3):481-486. PubMed ID: 28709991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity.
    Dimova D; Hu Y; Bajorath J
    J Med Chem; 2012 Nov; 55(22):10220-8. PubMed ID: 23050678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Badapple: promiscuity patterns from noisy evidence.
    Yang JJ; Ursu O; Lipinski CA; Sklar LA; Oprea TI; Bologa CG
    J Cheminform; 2016; 8():29. PubMed ID: 27239230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-stoichiometric inhibition in integrated lead finding - a literature review.
    Klumpp M
    Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationalizing Promiscuity Cliffs.
    Dimova D; Bajorath J
    ChemMedChem; 2018 Mar; 13(6):490-494. PubMed ID: 29024534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analyzing compound activity records and promiscuity degrees in light of publication statistics.
    Hu Y; Bajorath J
    F1000Res; 2016; 5():. PubMed ID: 27347396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research.
    Pouliot M; Jeanmart S
    J Med Chem; 2016 Jan; 59(2):497-503. PubMed ID: 26313340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rules for identifying potentially reactive or promiscuous compounds.
    Bruns RF; Watson IA
    J Med Chem; 2012 Nov; 55(22):9763-72. PubMed ID: 23061697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can we discover pharmacological promiscuity early in the drug discovery process?
    Peters JU; Hert J; Bissantz C; Hillebrecht A; Gerebtzoff G; Bendels S; Tillier F; Migeon J; Fischer H; Guba W; Kansy M
    Drug Discov Today; 2012 Apr; 17(7-8):325-35. PubMed ID: 22269136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-Promiscuity Relationship Puzzles-Extensively Assayed Analogs with Large Differences in Target Annotations.
    Hu Y; Jasial S; Gilberg E; Bajorath J
    AAPS J; 2017 May; 19(3):856-864. PubMed ID: 28265982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS).
    Baell JB
    J Nat Prod; 2016 Mar; 79(3):616-28. PubMed ID: 26900761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How promiscuous are pharmaceutically relevant compounds? A data-driven assessment.
    Hu Y; Bajorath J
    AAPS J; 2013 Jan; 15(1):104-11. PubMed ID: 23090085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Towards a systematic assessment of assay interference: Identification of extensively tested compounds with high assay promiscuity.
    Gilberg E; Stumpfe D; Bajorath J
    F1000Res; 2017; 6():. PubMed ID: 28928939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design.
    Gilberg E; Stumpfe D; Bajorath J
    ACS Omega; 2018 Jan; 3(1):106-111. PubMed ID: 30023769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.
    Baell JB; Holloway GA
    J Med Chem; 2010 Apr; 53(7):2719-40. PubMed ID: 20131845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.